Suchergebnisse - "Niger, Monica"

PubPharm (5)

1

Adverse events during first-line treatments for mCRC : The Toxicity over Time (ToxT) analysis of three randomised trials

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Boccaccino, A. | Rossini, D. | Raimondi, A. | +16

CommentOn: Lancet Haematol. 2020 Jun;7(6):e490-e497. - PMID 32470440

2

FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer : A Propensity Score-Based Analysis

enthalten in: The oncologist | 2021

von Pietrantonio, F. | Fucà, G. | Rossini, D. | +17

3

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab : a clinical and translational study

enthalten in: Journal of translational medicine | 2016

von Pietrantonio, F. | Berenato, R. | Maggi, C. | +17

4

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

enthalten in: Journal of translational medicine | 2016

von Pietrantonio, F. | Berenato, R. | Maggi, C. | +17

5

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

enthalten in: Journal of translational medicine | 2016

von Pietrantonio, F. | Berenato, R. | Maggi, C. | +17

1
[1]